Inhibitor Therapeutics, Inc.
INTIDrugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How INTI's past catalysts played out
No drugs found in this phase.
Hormone receptor-positive, HER2-negative metastatic breast cancer
1 drug in this indication
Systemic Lupus Erythematosus (SLE)
1 drug in this indication
Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
1 drug in this indication
nonsegmental vitiligo
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is Inhibitor Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Inhibitor Therapeutics, Inc. (INTI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track INTI biotech catalysts?→
Add INTI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inhibitor Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.